-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1668 Pediatrics Non-Hodgkin’s Lymphoma Survivors: Should We Worry about Quality of Life and Late Therapy Effects?

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Lymphomas, non-Hodgkin lymphoma, Clinical Research, pediatric, Diseases, aggressive lymphoma, Lymphoid Malignancies, survivorship, Study Population, Human
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Azza Ali Fahmy Ayad, MSc1*, Reham Abdelaziz Khedr, MD2,3, Asmaa Mohammed Hamoda, MD, PhD, MSc4*, Tamer Diab5*, Nahla Elnabarawy6*, Elhamy Rifky7*, Leslie E. Lehmann, MD8,9,10 and Alaa M. Elhaddad, MD11,12

1Pediatric Oncology, Children's cancer Hospital Egypt 57357, Cairo, EGY
2Pediatric oncology, Chlidren’s Cancer Hospital Egypt 57357, Cairo, Egypt
3Pediatric oncology, National Cancer Institute - Cairo university, Cairo, Egypt
4National cancer Institute- Cairo University / CCHE57357, Cairo, EGY
5Psychology department, Children's Cancer hospital Egypt, cairo, Egypt
6Children's cancer hospital Egypt 57357, cairo, Egypt
7Children's cancer hospital 57357Egypt, cairo, Egypt
8Department of Pediatrics, Harvard Medical School, Boston, MA
9Dana Farber Cancer Institute/Boston Children's Hospital, Boston, MA
10Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
11Department of Pediatric Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Cairo University, Cairo, Egypt
12Department of Pediatric Oncology and Stem Cell Transplantation Unit, Children Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt

Background: The survival outcomes of mature B-cell non-Hodgkin lymphoma (NHL) patients have improved due to advances in treatment. Objectives: In this study, we aim to assess the frequency and trends of the late effects and their impact on the quality of life among these survivors at Children Cancer Hospital Egypt Design and methods: A retrospective study including all patients diagnosed with Non-Hodgkin’s lymphoma “Mature B” at CCHE 57357 in the period between January 2012 till December 2015. All of the patients were examined clinically and assessed for: Cognitive functions (by assessing IQ level using (Stanford-Binet Intelligence Scales, Fifth Edition ‘’SB5’’), Cardiac function, Endocrine function (Thyroid functions, Growth curves), Pulmonary function (pulmonary function test), Lipid profile (triglyceride, cholesterol, HDL, LDL) and Quality of life assessment (PedsQL) Results: A total of 345 patients were diagnosed of having mature B cell lymphoma during the study period. 213 were evaluable with a male: female ratio 4:1. Staging: stage I (7.5%), II (14.1%), III (58.7%), IV (19.7%). patients < 5 years of age tend to have more affection than those > 5 years. The total mean QoL score 99 ± 0.058, the order of the affected domains, according to severity: physical functioning 92 ± 0.1, emotional functioning 92 ± 0.15, followed by social functioning 97 ± 0.08, school functioning 99 ± 0.06. IQ scores (low average 24.4%, high average 10.3%, average 63.8%). Pulmonary functions test was evaluated in 123 patients with affection detected in (57.7%) as follows: (mild degree 34.2%, moderate 14%, severe 9.3%). Cardiac reported with early onset 22% (from which 63% resolved, 36% persistent), late-onset 10.3%. Lipid profile was significantly affected, showing dyslipidemia 61.9% (high triglycerides 21.6%, low HDL 16%, high LDL 8.9%, and high total cholesterol 41.8%) while Growth affection: regarding weight (25.4% dropped 2 or more centiles, height (33.3% dropped 2 or more centiles) Conclusion: long term NHL survivors, pulmonary and cardiac functions should be followed up for possible affection. Lipid profiles and weight affection should be monitored closely. A survivorship program for NHL in children is recommended.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH